Episode: Is thymectomy an effective option for myasthenia gravis (MG) patients?


Neurology Today - Neurology Today Podcast Logo
Subscribe
Is thymectomy an effective option for myasthenia gravis (MG) patients?
The first randomized, placebo-controlled trial to examine that question suggests that it is. Neurology Today speaks with the study principals — Gil I. Wolfe, MD, FAAN, the Irvin and Rosemary Smith professor and chair in the department of neurology at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences of SUNY, and Gary Cutter, PhD, professor of biostatistics at University of Alabama at Birmingham School of Public Health, about the long road to providing class 1 evidence for the therapy. Read the Neurology Today article: http://bit.ly/NT-thymectomy.

Neurology Today - Neurology Today Podcast
Users who viewed this episode also viewed...

Analytics on Fire > Analytics on Fire - Ep.1 - Introduction

Analytics on Fire is the leading business intelligence and data visualization podcast. Every week Mico Yuk (BIBrainz) and Ryan Goodman (Centigon Solutions) bring you incredible interviews from some of the worlds best BI leaders and practitioners.  In this episode they discuss what you can expect from the Analytics on Fire podcast and how YOU can get involved...

Neurology Today - Neurology Today Podcast > LISTEN UP: DUCHENNE MUSCULAR DYSTROPHY: What happened to 20-year-old comparative data on two corticosteroids for Duchenne muscular dystrophy (DMD) — and what does it mean for the DMD therapy pipeline now?

The Food and Drug Administration is considering a new drug application for deflazacort based on data from a 1995 study released in Neurology. Here, the senior study author Robert C. Griggs, MD, FAAN, professor of neurology, medicine, pediatrics, pathology & laboratory medicine in the Center for Human Experimental Therapeutics at the University of Rochester School of Medicine and Dentistry, discusses what the findings could mean for DMD therapy...
Comments (0)

Login or Sign up to leave a comment.

Log in
Sign up

Be the first to comment.